IN2014DN07283A - - Google Patents

Info

Publication number
IN2014DN07283A
IN2014DN07283A IN7283DEN2014A IN2014DN07283A IN 2014DN07283 A IN2014DN07283 A IN 2014DN07283A IN 7283DEN2014 A IN7283DEN2014 A IN 7283DEN2014A IN 2014DN07283 A IN2014DN07283 A IN 2014DN07283A
Authority
IN
India
Prior art keywords
group
alkyl group
substituent
cancer agent
hydrogen atom
Prior art date
Application number
Inventor
Tetsuya Sugimoto
Hidekazu Takahashi
Morihiro Mitsuya
Norio Masuko
Hiroshi Sootome
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of IN2014DN07283A publication Critical patent/IN2014DN07283A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided are: a novel compound having an excellent Aurora A selective inhibitory activity and useful as an anti cancer agent that can be administered orally; a novel anti tumor effect enhancer for a microtube agonist comprising a taxane type anti cancer agent; and a combination therapy. A piperidine compound represented by general formula (I) (wherein R represents a carboxyl group C(=O)NRR or an oxadiazolyl group which may have a C C alkyl group or a trifluoromethyl group as a substituent; R represents a halogen atom or a C C alkoxy group; R represents a phenyl group which may have 1 to 3 groups independently selected from a halogen atom a C C alkyl group a C C alkoxy group and a trifluoromethyl group as a substituent or substituents; R represents a hydrogen atom or a C C alkyl group; and R and R may be the same as or different from each other and independently represent a hydrogen atom a C C alkyl group or a C C cycloalkyl group or R R and a nitrogen atom to which R and R are bound may together form a 3 to 6 membered nitrogenated saturated heterocyclic group) or a salt thereof.
IN7283DEN2014 2012-02-29 2013-02-27 IN2014DN07283A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012043303 2012-02-29
JP2012186534 2012-08-27
PCT/JP2013/055064 WO2013129443A1 (en) 2012-02-29 2013-02-27 Novel piperidine compound or salt thereof

Publications (1)

Publication Number Publication Date
IN2014DN07283A true IN2014DN07283A (en) 2015-04-24

Family

ID=49082638

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7283DEN2014 IN2014DN07283A (en) 2012-02-29 2013-02-27

Country Status (21)

Country Link
US (3) US9346787B2 (en)
EP (1) EP2821406B1 (en)
JP (1) JP5323289B1 (en)
KR (1) KR101677823B1 (en)
CN (1) CN104159893B (en)
AU (1) AU2013227024B2 (en)
BR (1) BR112014021519B1 (en)
CA (1) CA2865875C (en)
DK (1) DK2821406T3 (en)
ES (1) ES2576497T3 (en)
HK (1) HK1199730A1 (en)
HU (1) HUE028495T2 (en)
IN (1) IN2014DN07283A (en)
MX (1) MX344276B (en)
MY (1) MY169179A (en)
PL (1) PL2821406T3 (en)
PT (1) PT2821406T (en)
RU (1) RU2581834C1 (en)
SG (1) SG11201405318PA (en)
TW (1) TWI485146B (en)
WO (1) WO2013129443A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI485146B (en) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9012475B2 (en) 2013-08-27 2015-04-21 Taiho Pharmaceutical Co., Ltd. Method for enhancing anti-tumor effect of a microtubule-targeting drug, and a method for treatment of tumor
KR101430209B1 (en) * 2014-03-06 2014-08-14 강원대학교산학협력단 Diagnostic method for measuring protein kinase activity and diagnostic kit therefor
TWI693218B (en) * 2014-11-14 2020-05-11 美商美國禮來大藥廠 Aurora a kinase inhibitor
CN104758286B (en) * 2015-03-05 2016-09-14 南京工业大学 Application of 1-benzyl-4- (2, 4-dichlorophenethylamine) piperidine in preparation of antitumor drugs
WO2018117267A1 (en) 2016-12-22 2018-06-28 大鵬薬品工業株式会社 Salt of substituted piperidine compound
MA52793A (en) * 2018-05-29 2021-04-14 Taiho Pharmaceutical Co Ltd ANTI-TUMOR AGENT AND TUMOR TREATMENT METHOD
CN112239465A (en) * 2019-07-16 2021-01-19 微境生物医药科技(上海)有限公司 Aurora kinase inhibitor and use thereof
CN112898292A (en) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 Novel aurora kinase inhibitor and use thereof
TWI785474B (en) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 Novel heterocyclic compounds useful as selective aurora a inhibitors
CN117836285A (en) * 2021-07-28 2024-04-05 北京加科思新药研发有限公司 Polymorphic forms of AURORA a selective inhibitor and uses thereof
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors
WO2024088193A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. Combination of aurora a and parp inhibitors for treatment of cancers
WO2024088192A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002068415A1 (en) 2000-12-21 2002-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200621759A (en) * 2004-10-29 2006-07-01 Banyu Pharma Co Ltd Novel aminopyridine derivatives having aurora A selective inhibitory action
GB0509227D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
WO2007022384A2 (en) 2005-08-18 2007-02-22 Vertex Pharmaceuticals Incorporated Pyrazine kinase inhibitors
WO2007024843A2 (en) 2005-08-26 2007-03-01 Smithkline Beecham Corporation Pyrimidinyl-pyrazole inhibitors of aurora kinases
CA2622352C (en) 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
US20090221599A1 (en) * 2006-03-20 2009-09-03 Edward Boyd Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
CN101405001A (en) 2006-03-20 2009-04-08 霍夫曼-拉罗奇有限公司 Methods of inhibiting BTK and SYK protein kinases
JP2008081492A (en) * 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd New aminopyridine derivative having aurora a selective inhibitory action
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
US8519136B2 (en) 2008-02-22 2013-08-27 Msd K.K. Aminopyridine derivatives having aurora a selective inhibitory action
KR20110131302A (en) 2009-03-23 2011-12-06 엠에스디 가부시키가이샤 Novel aminopyridine derivatives having aurora a selective inhibitory action
CN102497863A (en) * 2009-03-24 2012-06-13 Msdk.K.公司 Novel aminopyridine derivatives having Aurora a selective inhibitory action
TWI485146B (en) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof

Also Published As

Publication number Publication date
US20160228427A1 (en) 2016-08-11
EP2821406B1 (en) 2016-06-01
ES2576497T3 (en) 2016-07-07
BR112014021519A2 (en) 2017-06-20
PL2821406T3 (en) 2016-11-30
PT2821406T (en) 2016-09-07
WO2013129443A1 (en) 2013-09-06
KR101677823B1 (en) 2016-11-18
MX2014010395A (en) 2015-06-05
EP2821406A4 (en) 2015-04-29
CN104159893B (en) 2016-05-11
AU2013227024A1 (en) 2014-09-18
CN104159893A (en) 2014-11-19
BR112014021519B1 (en) 2022-05-24
DK2821406T3 (en) 2016-08-22
AU2013227024B2 (en) 2015-12-10
SG11201405318PA (en) 2014-11-27
US20150045342A1 (en) 2015-02-12
US9346787B2 (en) 2016-05-24
CA2865875C (en) 2016-06-21
US10092556B2 (en) 2018-10-09
TW201339150A (en) 2013-10-01
JPWO2013129443A1 (en) 2015-07-30
CA2865875A1 (en) 2013-09-06
RU2581834C1 (en) 2016-04-20
KR20140129056A (en) 2014-11-06
HUE028495T2 (en) 2016-12-28
EP2821406A1 (en) 2015-01-07
US20180369224A1 (en) 2018-12-27
MY169179A (en) 2019-02-25
JP5323289B1 (en) 2013-10-23
TWI485146B (en) 2015-05-21
MX344276B (en) 2016-12-08
HK1199730A1 (en) 2015-07-17

Similar Documents

Publication Publication Date Title
IN2014DN07283A (en)
PH12018502633A1 (en) Substituted pyridines as inhibitors of dnmt1
PH12014501719A1 (en) Pyridone derivatives
CA2875877C (en) Syk inhibitors
NZ715747A (en) Syk inhibitors
MX2014011829A (en) N-substituted pyridinylidene compounds and derivatives for combating animal pests.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201690752A1 (en) INHIBITORS G12C KRAS
MX2013004407A (en) Pyridine derivative and medicinal agent.
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
EA201591753A1 (en) 3-PYRIMIDIN-4-ILOXAZOLIDIN-2-ONE AS MUTANT IDH INHIBITORS
MA34064B1 (en) HETEROCYCLIC COMPOUND
MX2013011551A (en) N-substituted hetero-bicyclic compounds and derivatives for combating animal pests.
EA201391629A1 (en) CSF-1R INHIBITORS FOR THE TREATMENT OF BRAIN TUMORS
RS52964B (en) 7-piperidinoalkyl-3,4-dihydroquinolone derivative
IN2014DN07509A (en)
RS54183B1 (en) Pyrazole derivatives
JO3509B1 (en) P2x7 modulators
EA201391558A1 (en) TETRAHYDROPYRAZOLO [1,5-A] Pyrimidine as an anti-tuberculosis compound
EA200900631A1 (en) SUBSTITUTED PYRAZOLES AND TRIAZOLES AS KIBB INHIBITORS (KYNESIN-PROTEIN VERETEN)
MX341341B (en) Benzamide derivatives and their use as hsp90 inhibtors.
WO2014102592A3 (en) Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
EP2585446A4 (en) Compounds having trpv1 antagonistic activity and uses thereof
MX2013007937A (en) Novel indole or indazole derivative or salt thereof.
MX2015007116A (en) New substituted 1,4-dithiine derivatives and their use as fungicides.